Aliases & Classifications for Blepharitis

MalaCards integrated aliases for Blepharitis:

Name: Blepharitis 12 74 36 54 6 43 15 17 71 32


External Ids:

Disease Ontology 12 DOID:9423
KEGG 36 H01644
ICD9CM 34 373.0 373.4
MeSH 43 D001762
NCIt 49 C112183
SNOMED-CT 67 41446000
ICD10 32 H01.0
UMLS 71 C0005741 C0155181

Summaries for Blepharitis

KEGG : 36 Blepharitis is a chronic inflammatory condition of the eyelids associated with itchiness, redness, flaking, and crusting. It is among the most common ocular conditions affecting both children and adults. The etiology is complex and not fully understood, but the general consensus is that bacteria and inflammation contribute to the pathology. Blepharitis can be classified into anterior blepharitis and posterior blepharitis. Anterior blepharitis describes inflammation of the eyelid skin and eyelash follicles and may be accompanied by squamous debris or collarettes. Anterior blepharitis has classically been associated with Staphylococcus infection and seborrheic dermatitis. Posterior blepharitis describes inflammation of the meibomian glands and their orifices and may be a result of or cause of meibomian gland dysfunction (MGD). MGD is one cause of posterior blepharitis but others include infectious or allergic conjunctivitis, and rosacea. The diagnosis of blepharitis is almost always based on the history and clinical examination. Long-term management of symptoms may include daily eyelid cleansing routines and the use of therapeutic agents that reduce infection and inflammation. Recent clinical trials have shown that antibiotics and topical corticosteroids can produce significant improvement in signs and symptoms of blepharitis.

MalaCards based summary : Blepharitis is related to blepharoconjunctivitis and rosacea, and has symptoms including erythema of the eyelids An important gene associated with Blepharitis is STAT1 (Signal Transducer And Activator Of Transcription 1), and among its related pathways/superpathways are Innate Immune System and PAK Pathway. The drugs Permethrin and Fusidic Acid have been mentioned in the context of this disorder. Affiliated tissues include eye, skin and testes, and related phenotypes are digestive/alimentary and immune system

Disease Ontology : 12 An eyelid disease that is characterized by often chronic inflammation of the eyelid, generally the part where eyelashes grow.

Wikipedia : 74 Blepharitis is one of the most common ocular conditions characterized by inflammation, scaling,... more...

Related Diseases for Blepharitis

Diseases related to Blepharitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 411)
# Related Disease Score Top Affiliating Genes
1 blepharoconjunctivitis 32.7 IL4 DCXR CD4
2 rosacea 31.2 TNF MMP9 CCR6
3 eyelid disease 31.1 TNF MUC5AC MUC16 MMP9 LACRT DCXR
4 dermatophytosis 31.0 LTF CD4 CCR6
5 conjunctivitis 31.0 TNF MUC16 MMP9 IL4
6 seborrheic dermatitis 30.8 TNF CD4 CCR6
7 keratitis, hereditary 30.8 TNF CD4 CCR6
8 keratopathy 30.7 TNF LACRT IL4
9 keratoconjunctivitis 30.4 TNF MUC5AC MUC16 MMP9 IL4
10 pyoderma 30.2 TNF MMP9 CCR6
11 vernal conjunctivitis 30.1 MUC5AC IL4 CCR6
12 allergic contact dermatitis 30.1 TNF IL4 CD4
13 contact dermatitis 30.1 TNF IL4 CD4
14 folliculitis 30.0 TNF MBTPS2 IL4 CD4 CCR6
15 allergic hypersensitivity disease 29.8 TNF IL4 CD4 CCR6
16 crohn's disease 29.7 TNF IL4 CD4 CCR6
17 dry eye syndrome 29.7 TNF PIP MUC5AC LTF LCN1 LACRT
18 skin disease 29.6 TNF IL4 CD8A CD4 CCR6
19 eye disease 29.6 TNF MMP9 LACRT IL4 CD8A CD4
20 immune deficiency disease 29.5 TNF STAT1 IL4 CD4 CCR6
21 dermatitis, atopic 29.5 TNF STAT1 IL4 CD8A CD4 CCR6
22 keratoconjunctivitis sicca 29.5 TNF MUC5AC LTF LACRT IL4 CD4
23 bacterial infectious disease 29.4 TNF LTF CD8A CD4 CCR6
24 fungal infectious disease 29.1 TNF STAT1 IL4 CD8A CD4 CCR6
25 systemic lupus erythematosus 28.7 TNF STAT1 MMP9 LTF IL4 CD8A
26 ulcerative blepharitis 12.5
27 squamous blepharitis 12.5
28 meibomian cyst 11.5
29 focal facial dermal dysplasia 3, setleis type 11.3
30 keratosis follicularis spinulosa decalvans, x-linked 11.3
31 ectodermal dysplasia 15, hypohidrotic/hair type 11.3
32 ichthyosis, congenital, autosomal recessive 11 11.2
33 ectodermal dysplasia/skin fragility syndrome 11.2
34 hordeolum externum 11.2
35 geotrichosis 10.5 STAT1 CD4
36 autoimmune inner ear disease 10.5 TNF MMP9
37 nail disorder, nonsyndromic congenital, 1 10.4 MBTPS2 CCR6
38 herpes simplex 10.4
39 anal canal adenocarcinoma 10.4 PIP MUC5AC
40 parotitis 10.4 MMP9 LTF CD4
41 hyper ige recurrent infection syndrome 1 10.4 STAT1 CD4 CCR6
42 lupus erythematosus 10.4
43 corneal ulcer 10.3 MUC5AC MMP9 LACRT
44 haemophilus influenzae 10.3 TNF LTF
45 rheumatoid arthritis interstitial lung disease 10.3 TNF CD4
46 tropical endomyocardial fibrosis 10.3 TNF IL4
47 telangiectasis 10.3
48 chronic salpingitis 10.3 TNF MUC16
49 myelitis 10.3 TNF MMP9 CCR6
50 anal paget's disease 10.3 PIP DCXR

Comorbidity relations with Blepharitis via Phenotypic Disease Network (PDN):

Acute Cystitis Conjunctivitis
Deficiency Anemia Familial Atrial Fibrillation
Heart Disease Hypertension, Essential
Parkinson Disease, Late-Onset Schizophreniform Disorder

Graphical network of the top 20 diseases related to Blepharitis:

Diseases related to Blepharitis

Symptoms & Phenotypes for Blepharitis

UMLS symptoms related to Blepharitis:

erythema of the eyelids

MGI Mouse Phenotypes related to Blepharitis:

# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 CD4 IL4 MMP9 MUC5AC PIP PLA2G1B
2 immune system MP:0005387 9.36 CCR6 CD4 CD8A IL4 LTF MMP9

Drugs & Therapeutics for Blepharitis

Drugs for Blepharitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Permethrin Approved, Investigational Phase 4 52645-53-1 40326
Fusidic Acid Approved, Investigational Phase 4 6990-06-3 3000226
Chloramphenicol Approved, Vet_approved Phase 4 56-75-7 298 5959
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
Tobramycin Approved, Investigational Phase 4 32986-56-4 36294 5496
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
Besifloxacin Approved Phase 4 141388-76-3
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 9865442 444025
Iodine Approved, Investigational Phase 4 7553-56-2 807
Povidone-iodine Approved Phase 4 25655-41-8
Povidone Approved Phase 4 9003-39-8
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Ofloxacin Approved Phase 4 82419-36-1 4583
19 Dermatologic Agents Phase 4
20 Butylated Hydroxytoluene Phase 4
21 Keratolytic Agents Phase 4
22 Anti-Bacterial Agents Phase 4
23 Anti-Infective Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Anti-Infective Agents, Local Phase 4
26 Erythromycin Estolate Phase 4
27 Erythromycin stearate Phase 4
28 Erythromycin Ethylsuccinate Phase 4
29 Anti-Allergic Agents Phase 4
30 Adjuvants, Immunologic Phase 4
31 Viscosupplements Phase 4
32 Protective Agents Phase 4
33 Immunologic Factors Phase 4
34 Plasma Substitutes Phase 4
35 cadexomer iodine Phase 4
36 Blood Substitutes Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4
38 Disinfectants Phase 4
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
Metronidazole Approved Phase 3 443-48-1 4173
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
Dipivefrin Approved Phase 3 52365-63-6 3105
Ciprofloxacin Approved, Investigational Phase 2, Phase 3 85721-33-1 2764
Acyclovir Approved Phase 3 59277-89-3 2022
46 Hormones Phase 3
47 glucocorticoids Phase 3
48 Hormone Antagonists Phase 3
49 Tobramycin, Dexamethasone Drug Combination Phase 3
50 Antineoplastic Agents, Hormonal Phase 3

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial. Unknown status NCT03105505 Phase 4 Permethrin 5%;Synthomycine 5%;Fusidic Acid 1% M/R Eye Drops
2 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
3 Efficacy and Safety of Posiformin 2 % Eye Ointment in the Treatment of Blepharitis - a Multi-centre, Randomised, Double-masked, Parallel-group, Phase IV Comparison Completed NCT01357538 Phase 4 Posiformin 2 %, bibrocathol;Placebo Comparator
4 A Multi-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone in Subjects With Blepharitis Completed NCT00629980 Phase 4 AzaSite®
5 A Multi-Center, Open-Label Study Evaluating the Cytokine and Eyelid Margin Bacterial Load Levels of Subjects Diagnosed With Chronic Blepharitis Following Dosing With AzaSite® (Azithromycin Ophthalmic Solution) 1% Completed NCT00629941 Phase 4 AzaSite®
6 A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Two Weeks in Subjects With Posterior Blepharitis Completed NCT00629590 Phase 4 AzaSite®
7 A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Four Weeks in Subjects With Posterior Blepharitis Completed NCT00656539 Phase 4 AzaSite®
8 A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis Completed NCT01478256 Phase 4 Erythromycin;Besifloxocin
9 Randomized Double-Blind Trial of Lid Wipes Containing Terpinen-4-ol and Sodium Hyaluronate Versus Baby Shampoo in Patients With Seborrheic Blepharitis Completed NCT04441528 Phase 4 Lid wipes containing terpinen-4-ol and sodium hyaluronate;Baby shampoo
10 Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol/Tobramycin (Zylet®) in Treatment of Chronic Ocular Surface Inflammation Associated With Meibomian Gland Dysfunction (MGD)/Posterior Blepharitis Completed NCT01456780 Phase 4 Loteprednol/tobramycin;Loteprednol;B+L Advanced Eye Relief Lubricant Drop
11 Lipids of the Human Tear Film and Their Effect on Tear Stability Completed NCT00803452 Phase 4 doxycycline;azithromycin
12 Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) Completed NCT04018482 Phase 4
13 Phase 4 Study on Effectiveness of Topical 0.5% Levofloxacin on Reduction of Preoperative Conjunctival Flora in Patients Scheduled for Intraocular Surgery Completed NCT00491049 Phase 4 0.5% levofloxacin eye drops
14 A Phase 4 Study to Assess the Clinical Efficacy and Safety of Manuka Eye Drops for Treatment of Allergy Withdrawn NCT03862053 Phase 4 Manuka honey
15 A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis Completed NCT01102244 Phase 3 Tobradex ST;Azasite
16 A Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-502 Compared to AzaSite Alone, Dexamethasone Alone, and Vehicle in the Treatment of Subjects With Non-Bacterial Blepharitis Completed NCT01408082 Phase 3 ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined);Azasite;Dexamethasone
17 Diagnosis of Demodex Blapharitis and Treatment With Ivermectin Gel 0.1%/ Metronidazole 1% Completed NCT02236403 Phase 3 Ivermectin 0.1% Metronidazole 1%
18 An Evaluation of the Safety and Efficacy of the Administration of a Fixed Combination of Moxifloxacin 0.5% and Dexamethasone 0.1% Eye Drops Compared With the Individual Administration of Moxifloxacin 0.5% and Dexamethasone 0.1% in the Treatment of Bacterial Ocular Inflammation and Infection (Blepharitis and/or Keratitis and/or Conjunctivitis) Completed NCT00732446 Phase 3 Moxifloxacin and Dexamethasone combined;Moxifloxacin;Dexamethasone
19 Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes Completed NCT00796926 Phase 3 Systane Ultra eyedrops;Refresh eye drops
20 A Clinical Safety and Efficacy Evaluation of Zylet® Versus Tobradex in the Treatment of Blepharokeratoconjunctivitis Completed NCT01028027 Phase 3 Loteprednol and tobramycin;Tobramycin and dexamethasone
21 A Randomized Controlled Trial of Treatment Efficacy in Ameliorating Demodex Spp. Infestation Among Cases Undergoing Cataract Surgery Completed NCT04204954 Phase 2, Phase 3 Ciprofloxacin Ophthalmic Ointment 0.3%
22 Herpetic Eye Disease Study (HEDS) II Completed NCT00000139 Phase 3 Acyclovir
23 A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis Active, not recruiting NCT01543490 Phase 3 ISV-305
24 Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection Withdrawn NCT01721694 Phase 3 azithromycin 1.5%/Loteprednol 0,5% + placebo;azithromycin 1.5% + Loteprednol 0,5% (separately)
25 Efficacy and Safety of COL-101 for the Treatment of Blepharitis in Patients With Facial Rosacea Completed NCT00560703 Phase 2 COL-101 (doxycycline, USP) capsules;placebo
26 Safety and Efficacy of Topical Interleukin-1-Receptor Antagonist in the Treatment of Signs and Symptoms of Posterior Blepharitis Completed NCT00681109 Phase 1, Phase 2 2.5% IL-1Ra;Placebo;5% IL-1Ra
27 Tea Tree Oil in the Treatment of Chronic Blepharitis Completed NCT01073150 Phase 2 Tea Tree Oil
28 Study of the Effect of Oral Azithromycin on Posterior Blepharitis Completed NCT01783860 Phase 2 Azithromycin;Doxycycline
29 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638) Completed NCT00894530 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
30 The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period Completed NCT00892970 Phase 2 Azithromycin ophthalmic solution, 1%;Placebo
31 A Multi-Center, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Phase 2 Study Evaluating the Safety and Tolerability of NCX 4251 (Fluticasone Propionate Nanocrystal) Ophthalmic Suspension, 0.1% QD and BID for the Treatment of Acute Exacerbations of Blepharitis Completed NCT03926026 Phase 2 Fluticasone Propionate;Placebo
32 Efficacy and Safety Assessment of Azyter® Eye Drops (T1225) in Patients With Blepharitis (Pilot Phase II Clinical Study, Multicentre, Randomised, Double Masked, Comparative, 2 X 40 Patients) Completed NCT01089608 Phase 2 Azithromycin;Povidone
33 A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease Completed NCT02218489 Phase 2 KPI-121;Vehicle
34 A Single-Center, Double-Masked, Randomized, Vehicle Controlled Study to Evaluate the Safety and Efficacy of Testosterone 0.03% Ophthalmic Solution Compared to Vehicle for the Treatment of Meibomian Gland Dysfunction Completed NCT00755183 Phase 2 testosterone ophthalmic solution;vehicle of testosterone ophthalmic solution
35 A Double-Masked, Randomized, Placebo-Controlled Study of ALTY-0501 (Doxycycline 0.025% Ophthalmic Solution) for the Treatment of Dry Eye Administered QID for a 56 Day Period Utilizing the Controlled Adverse Environment Model Completed NCT00439400 Phase 2 doxycycline;placebo
36 Evaluation and Treatment of Ocular Complications of Vaccinia Vaccination: Suitability of NP-016 Vaccinia Immune Globulin (VIG) for Sight-Threatening Conditions [VIG31] Completed NCT00081835 Phase 2 NP-016 Vaccine Immune Globulin (IV-VIG)
37 A Randomized, Multi-Center, Double-Masked, Vehicle-Controlled, Parallel-Group, Safety and Efficacy Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle for Four Weeks in Subjects With Blepharitis Terminated NCT01269658 Phase 2 Azithromycin ophthalmic solution, 1%;Vehicle
38 An Evaluation of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates Terminated NCT00579020 Phase 2 Moxifloxacin/dexamethasone phosphate ophthalmic solution;Moxifloxacin ophthalmic solution 0.5%;Dexamethasone phosphate solution, 0.1%
39 Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial Completed NCT01647217 Phase 1 Terpinen-4-ol
40 Ocular Comfort and Markers of Inflammation in Subjects Undergoing Lid Hygiene Therapy Unknown status NCT02938078
41 Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis: A Randomized, Outcomes-Assessor Masked, Clinical Trial Unknown status NCT03422146
42 Effect of Ocular Hygiene on Scleral Lens Wear Unknown status NCT03544385 Early Phase 1 Ringers Solution;Placebo - Concentrate
43 A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora Unknown status NCT02455895
44 Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug in Patients With Open Angle Early Visual Field Defects Glaucoma or Ocular Hypertension in Comparison to Xalatan © Eye Drops in the Second Eye Unknown status NCT03318146 XALATAN®
45 Blephacura Versus Baby Shampoo to Treat Blepharitis Completed NCT01115192
46 Randomized, Controlled Study With a Closed Sequential Design to Compare the Efficacy, Safety and Patient Satisfaction of Blephapad Combo vs. Standard Treatment for Eyelid Cleansing in Patients Affected by Bilateral Posterior Blepharitis. Completed NCT03301844
47 Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis Completed NCT02952079
48 Investigation of Chronic Inflammatory Processes in the Respiratory Tract and the Eyes of Male Individuals With X-linked Hypohidrotic Ectodermal Dysplasia Completed NCT01308333
49 Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery Completed NCT01808560
50 Evaluation and Treatment of Corneal and External Diseases and Anterior Segment Disorders Completed NCT00008541

Search NIH Clinical Center for Blepharitis

Cochrane evidence based reviews: blepharitis

Genetic Tests for Blepharitis

Anatomical Context for Blepharitis

MalaCards organs/tissues related to Blepharitis:

Eye, Skin, Testes, T Cells, Bone Marrow, Bone, Brain

Publications for Blepharitis

Articles related to Blepharitis:

(show top 50) (show all 1249)
# Title Authors PMID Year
Influence of topical anesthesia on tests diagnostic of blepharitis-associated dry eye syndrome. 54 61
9145691 1997
Effect of Eyelid Treatments on Bacterial Load and Lipase Activity in Relation to Contact Lens Discomfort. 61
31794542 2020
Dry anophthalmic socket syndrome - Standardized clinical evaluation of symptoms and signs. 61
32387569 2020
Novel In-Office Technique for Visual Confirmation of Demodex Infestation in Blepharitic Patients. 61
32049679 2020
Next-Generation Sequencing of the Ocular Surface Microbiome: In Health, Contact Lens Wear, Diabetes, Trachoma, and Dry Eye. 61
32443013 2020
Mycoplasma Pneumoniae Induced Rash and Mucositis (MIRM): A Longitudinal Perspective and Proposed Management Criteria. 61
32574770 2020
Ocular Surface Disorders in Patients with Human Immunodeficiency Virus (HIV) Infection. 61
32501744 2020
Ocular Anterior Segment Pathology in the Emergency Department: A 5-Year Study. 61
32568931 2020
Pre-operative conjunctival flora in patients with local and/or systemic risk factors for post cataract surgery infection in Northern Italy. 61
32552180 2020
Severe allergic contact blepharitis from propolis. 61
32112421 2020
Spontaneous Cataractous Lens Extrusion in a Patient with Corneal Melting. 61
32508625 2020
The Efficacy of Warm Compresses in the Treatment of Meibomian Gland Dysfunction and Demodex Folliculorum Blepharitis. 61
31657234 2020
Topical ivermectin-metronidazole gel therapy in the treatment of blepharitis caused by Demodex spp.: A randomized clinical trial. 61
32461053 2020
Increased frequency of Demodex blepharitis in rosacea and facial demodicosis patients. 61
31553138 2020
Molecular and phenotypic characterization of methicillin-resistant Staphylococcus pseudintermedius from ocular surfaces of dogs and cats suffering from ophthalmological diseases. 61
32402352 2020
Ocular Findings in Pontine Tegmental Cap Dysplasia. 61
32398424 2020
Randomized trial of topical periocular castor oil treatment for blepharitis. 61
32422285 2020
Safety and Efficacy of Long-Term Ripasudil 0.4% Instillation for the Reduction of Intraocular Pressure in Japanese Open-Angle Glaucoma Patients. 61
32175792 2020
Palpebral and facial skin infestation by Demodex folliculorum. 61
31563449 2020
Prevalence of Demodex spp. in eyelashes of a university's population in Santiago, Chile. 61
32067802 2020
Efficacy of Topical Ivermectin for the Treatment of Cutaneous and Ocular Rosacea. 61
32255398 2020
Enhanced orbital adipogenesis in a mouse model of T-cell-mediated autoimmunity, zymosan A-treated SKG mice: Implications for Graves' ophthalmopathy. 61
32355208 2020
Eye care providers' emerging roles in early detection of diabetes and management of diabetic changes to the ocular surface: a review. 61
32299899 2020
A Case of Sebaceous Adenitis and Concurrent Meibomian Gland Dysfunction in a Dog. 61
32252394 2020
Efficacy of cyclic therapy with terpinen-4-ol in Demodex blepharitis: Is treatment possible by considering Demodex's life cycle? 61
32329361 2020
Double-Masked and Unmasked Prospective Study of Terpinen-4-ol Lid Scrubs With Microblepharoexfoliation for the Treatment of Demodex Blepharitis. 61
31939919 2020
The effect of lid hygiene on the tear film and ocular surface, and the prevalence of Demodex blepharitis in university students. 61
31548151 2020
Blepharitis Caused by Demodex 61
32212585 2020
Deployed ophthalmic workload in support of US and NATO operations in Afghanistan. 61
32139414 2020
Atypical herpes simplex keratitis: frequency, clinical presentations and treatment results. 61
31754891 2020
Ocular alignment, media, and eyelid disorders in Down syndrome. 61
31830843 2020
Lupus Miliaris Disseminatus Faciei of the Posterior Eyelids: A Case Report. 61
32049944 2020
A Review on Evidence-Based Treatments for Meibomian Gland Dysfunction. 61
31834043 2020
[Treatment of chronic posterior blepharitis after allogeneic hematopoietic stem cell transplantation (a case report)]. 61
32366075 2020
Itching eyes after itching around the head. 61
32269907 2020
STAT1 gain-of-function and chronic demodicosis. 61
31637766 2020
Randomized masked trial of the clinical efficacy of MGO Manuka Honey microemulsion eye cream for the treatment of blepharitis. 61
31759183 2020
The Clinical Use of Eyelash Manipulation in the Diagnosis of Demodex Folliculorum Blepharitis. 61
31469758 2020
The Clinical Use of Eyelash Manipulation in the Diagnosis of Demodex Folliculorum Blepharitis. 61
31834045 2020
The Clinical Use of Eyelash Manipulation in the Diagnosis of Demodex folliculorum Blepharitis. 61
30950926 2020
[Treatment of chronic blepharitis]. 61
32241975 2020
Prevalence and Associated Factors of Pterygium Among Adults Living in Kolla Diba Town, Northwest Ethiopia. 61
32099312 2020
Ripasudil Hydrochloride Hydrate in the Treatment of Glaucoma: Safety, Efficacy, and Patient Selection. 61
32440089 2020
Short-Term Efficacy and Safety of Switching from a Latanoprost/Timolol Fixed Combination to a Latanoprost/Carteolol Fixed Combination. 61
32440086 2020
Corneal Ulcer Treated with 0.66% Nanoemulsion Povidone-Iodine: A Case Report. 61
31974332 2020
Prevalence and Treatment Outcome of Nasolacrimal Duct Obstruction in Saudi Children with Down Syndrome. 61
31976186 2020
28858192 2020
Improved Demodex diagnosis in the clinical setting using a novel in situ technique. 61
31806355 2019
The effect of Blephadex™ Eyelid Wipes on Demodex mites, ocular microbiota, bacterial lipase and comfort: a pilot study. 61
31239200 2019
MEN 2B masquerading as chronic blepharitis and euryblepharon. 61
30688132 2019

Variations for Blepharitis

ClinVar genetic disease variations for Blepharitis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln)SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184

Expression for Blepharitis

Search GEO for disease gene expression data for Blepharitis.

Pathways for Blepharitis

Pathways related to Blepharitis according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
12.69 TNF STAT1 IL4 CD8A CD4
Show member pathways
Show member pathways
6 11.78 TNF PLA2G6 MMP9 IL4
7 11.73 TNF IL4 CD8A CD4
Show member pathways
11.69 STAT1 IL4 CD4
9 11.68 TNF STAT1 MMP9 IL4
Show member pathways
11.61 STAT1 IL4 CD8A CD4
11 11.59 STAT1 MMP9 CD4
12 11.57 TNF CD8A CD4
13 11.45 TNF MMP9 IL4
14 11.25 TNF IL4 CD8A CD4
15 10.92 TNF IL4 CD8A CD4 CCR6
16 10.79 TNF IL4 CD4

GO Terms for Blepharitis

Cellular components related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.81 PIP MUC5AC MUC4 MUC16 MMP9 LTF
2 extracellular region GO:0005576 9.8 TNF PLA2G1B PIP MUC5AC MUC4 MUC16
3 extracellular space GO:0005615 9.44 TNF PLA2G6 PLA2G1B PIP MUC5AC MUC4

Biological processes related to Blepharitis according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 TNF IL4 CD8A CD4 CCR6
2 positive regulation of protein phosphorylation GO:0001934 9.71 TNF PLA2G6 MMP9 CD4
3 O-glycan processing GO:0016266 9.63 MUC5AC MUC4 MUC16
4 humoral immune response GO:0006959 9.61 TNF LTF CCR6
5 cytokine-mediated signaling pathway GO:0019221 9.55 TNF STAT1 MMP9 IL4 CD4
6 positive regulation of chemokine biosynthetic process GO:0045080 9.54 TNF IL4
7 positive regulation of calcium ion transport into cytosol GO:0010524 9.52 PLA2G1B CD4
8 positive regulation of ceramide biosynthetic process GO:2000304 9.51 TNF PLA2G6
9 T cell activation GO:0042110 9.5 IL4 CD8A CD4
10 negative regulation of lipopolysaccharide-mediated signaling pathway GO:0031665 9.49 LTF LACRT
11 antibacterial humoral response GO:0019731 9.43 PLA2G6 PLA2G1B LTF
12 positive regulation of mononuclear cell migration GO:0071677 9.37 TNF IL4
13 innate immune response in mucosa GO:0002227 9.13 PLA2G1B LTF IL4
14 retina homeostasis GO:0001895 8.92 PIP LTF LCN1 CST4

Molecular functions related to Blepharitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase inhibitor activity GO:0004869 8.92 LTF LCN1 CST6 CST4

Sources for Blepharitis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....